FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

FORTUNOFF GREGORY

2. Date of Event Requiring Statement (MM/DD/YYYY)
1/2/2018 

3. Issuer Name and Ticker or Trading Symbol

Medite Cancer Diagnostics, Inc. [MDIT]

(Last)        (First)        (Middle)

C/O MEDITE CANCER DIAGNOSTICS, INC., 4203 SW 34TH ST.

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                            _____ 10% Owner
_____ Officer (give title below)          _____ Other (specify below)

(Street)

ORLANDO, FL 32811       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock   200000   D  
 

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant   3/28/2017   3/28/2022   Common Stock   50000   $0.50   D  
 
Warrant   5/17/2017   5/17/2022   Common Stock   50000   $0.50   D  
 
Secured Convertible Note   9/27/2017   9/27/2020   Common Stock   300000   $0.65   D  
 
Warrant   9/27/2017   3/26/2022   Common Stock   236687   $0.60   D  
 
Secured Convertible Note   12/21/2017   12/21/2020   Common Stock   200000   $0.65   D  
 
Warrant   12/21/2017   12/21/2022   Common Stock   157791   $0.60   D  
 

Explanation of Responses:

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
FORTUNOFF GREGORY
C/O MEDITE CANCER DIAGNOSTICS, INC.
4203 SW 34TH ST.
ORLANDO, FL 32811 		X



Signatures
/s/ Greg Fortunoff 5/8/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Medite Cancer Diagnostics (CE) (USOTC:MDIT)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Medite Cancer Diagnostics (CE) Charts.
Medite Cancer Diagnostics (CE) (USOTC:MDIT)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Medite Cancer Diagnostics (CE) Charts.